Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
Pigmented Villonodular Synovitis|Tenosynovial Giant Cell Tumor
BIOLOGICAL: FPA008
The Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and Defined as Dose-limiting Toxicities (DLTs) in Phase 1, Number of participants with grade 3 and grade 4 adverse events (AE) defined as dose limiting toxicities (DLTs) in Phase 1, 52 weeks|The Incidence of Investigator-assessed, Confirmed Objective Responses (ORR) Per RECIST 1.1 (Phase 2), Number of confirmed objective responses (ORR) as assessed by the investigator per RECIST 1.1 (Phase 2), 52 weeks
PK Parameters of Cabiralizumab: Area Under Concentration-time Curve (AUC), Area under serum concentration-time curve (AUC) for cabiralizumab as a PK parameter, 52 weeks|Maximum Serum Concentration (Cmax)., Composite PK parameters of cabiralizumab: Maximum observed serum concentration, 52 weeks|Minimum Serum Concentration (Cmin)., Composite PK parameters of cabiralizumab: minimum serum concentration (Cmin)., 52 weeks|Pharmacokinetic Clearance (CL)., Composite PK parameters of cabiralizumab: clearance (CL), 52 weeks|The Incidence of AEs., treatment-emergent adverse events (TEAEs) by incidence for the Safety Population. Patients with at lease 1 TEAE., 52 weeks|The Incidence of Clinical Laboratory Abnormalities., The number of patients with a clinical laboratory that is outside the normal range at some time point during the study, 52 weeks|The Incidence of ECG Abnormalities., The number of patients who had a change in their ECG that were clinically significant, 52 weeks|Duration of Response Per RECIST 1.1 in Phase 2, The length of response per RECIST 1.1 from the time of first response to progression or going off study in Phase 2, 52 weeks
A Phase 1/2 study was an open-label, dose escalation and dose expansion study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of cabiralizumab, a CSF1-R monoclonal antibody, inpatients with unresectable diffuse tenosynovial giant cell tumors (TGCT).